|
Kirkland, Washington
June 27, 2001
Rosetta Inpharmatics, Inc. (Nasdaq:RSTA), a leading
developer of gene expression data analysis software, and
Agilent Technologies Inc.
(NYSE:A) today announced that
Monsanto Company (NYSE:MON) has licensed the Rosetta
Resolver(R) Gene Expression Data Analysis System.
The Rosetta Resolver system is a bioinformatics system for gene
expression research developed by Rosetta Inpharmatics and
exclusively distributed by Agilent. The Rosetta Resolver system
can be used with a variety of third-party and internally
developed DNA microarray technologies, including Affymetrix
GeneChip(R)probe arrays and Agilent DNA microarrays.
"Monsanto's goal is to provide top-quality, cost-effective and
integrated approaches to help farmers improve their productivity
and produce better quality foods," said Dr. Christine Karslake,
director of business development of Monsanto Company. "The
Rosetta Resolver system, which will empower us to conduct
thorough and rapid analysis of our gene expression data, has
comprehensive features and high quality statistics that can help
us to quickly and efficiently develop products and solutions to
achieve our goal."
"We are pleased to add the world's leading provider of
agricultural solutions to our esteemed list of Rosetta Resolver
system customers," said Bill Buffington, vice president and
general manager of Agilent Technologies' Life Sciences Division.
"Monsanto joins three of the top pharmaceutical companies and
three of the top biotechnology companies who have been enabled
with the most comprehensive, robust tool for gene expression
data analysis."
About the Rosetta Resolver System
The Rosetta Resolver system provides high-capacity data storage,
retrieval and analysis of gene expression data. The system is
ideal for life science research organizations that need to
assess compound specificity or toxicity, identify new genes or
therapeutic targets, or compare and analyze large databases of
expression profiles. The Rosetta Resolver system combines
flexibility and ease of use with high-performance algorithms to
produce an enterprise solution for rapid
analysis of gene expression data. The system can accept and
analyze data from a wide variety of expression profiling
formats, including Affymetrix GeneChip Probe Arrays and Agilent
DNA microarrays, and applies Rosetta Inpharmatics' proprietary
error models to yield quality statistics for every gene
expression measurement. These statistics are automatically
leveraged by all analysis tools, ensuring reliable results. In
addition to Monsanto, many of the world's leading life science
organizations have licensed the Rosetta Resolver system,
including Biogen, DuPont Pharmaceuticals, GlaxoSmithKline, and
the Harvard University Center for Genomics Research. Additional
information about the Rosetta Resolver system can be found on
Rosetta Inpharmatics' Web site at
www.rii.com.
About Agilent Technologies
Agilent Technologies Inc. (NYSE:A) is a global technology leader
in communications, electronics, life sciences and healthcare.
With 48,000 employees serving customers in more than 120
countries, Agilent had net revenue of $10.8 billion in fiscal
year 2000. Information about Agilent can be found on the Web at
www.agilent.com.
About Rosetta Inpharmatics
Founded in December 1996, Rosetta Inpharmatics (Nasdaq:RSTA) is
an early leader in gene expression analysis. Its technology
solutions, including the Rosetta Resolver system, are designed
for many purposes, such as the potential to accelerate drug
discovery and agricultural product development by improving
biological data analysis. Gene expression analysis is
instrumental in many aspects of drug discovery and agricultural
product development. Information about Rosetta Inpharmatics can
be found on the Web at www.rii.com.
Resolver is a registered
trademark of Rosetta Inpharmatics, Inc.
GeneChip is a registered trademark of Affymetrix, Inc.
Company news release
N3616 |
